The Latest

• 

  Regeneron wins bid to buy 23andMe out of bankruptcy

  The biotech, which has for years invested in genetics research, plans to acquire "substantially all" of testing firm 23andMe's assets for $256 million.

  Pharma

• 

  With the third round of Medicare price negotiations on the way, here’s how the policy is shifting

  HHS issued guidance for the third cycle, teeing up another 15 drugs to be selected by early next year.  

  Pharma

• 

  Tracking a moving target: Drugmakers brace for a looming tariff impact

  With policies in flux, companies seek to be proactive and understand their supply chain.

  Manufacturing

• 

  A startup with Theranos ties has another blood test in the works. This time, competition is waiting.

  A stealth startup built by the partner of disgraced Theranos founder Elizabeth Holmes is taking a shot at a new blood test — an area where other companies are already making strides.

  Biotech

• 

  Q&A // First 90 Days

  A new CFO tasked with taking ‘scrappy’ Editas from last year’s layoffs into new gene editing territory

  Amy Parison, who stepped into the lead financial role at the company in March, is managing Editas Medicine’s transition to a new gene editing platform while recovering from a major overhaul.

  First 90 Days

• 

  Trump’s ‘most favored nation’ policy is back. Here’s why it failed the first time.

  The controversial plan aims to lower drug prices and will surely trigger another fight with pharma.

  Pharma

• 

  Women’s health faces growing headwinds, despite jump in venture investment

  While venture funding is rising, federal policy upheaval may affect women’s health research more acutely than other fields, one biotech CEO said.

  Pharma

• 

  With the breakneck speed of cancer breakthroughs, oncologists feel left behind. Can Big Pharma chime in?

  Community oncologists do their best to keep up with new treatments, but with the pace of cancer approvals, drugmakers need to team up with doctors on the front line.

  Leadership

• 

  FDA’s future in MAHA hands: How leadership is changing the agency’s trajectory

  Who’s in, who’s out and which key positions are still left to be filled in an agency upended.

  Leadership

• 

  Lupus R&D has come a long way, and the next breakthroughs could come from cell therapy

  But the therapies will need to prove their worth in the clinic over the next few years.

  Biotech

• 

  AI is already delivering pharma value — and not just in drug discovery

  While AI-generated drugs grab headlines, the technology is making more of an impact doing less “glamorous” tasks.

  Biotech

• 

  RFK Jr.’s autism fixation hearkens back to his stance on vaccines

  The head of HHS is seeking the “root causes” of autism spectrum disorder through a large government research project.

  Leadership

• 

  Alnylam keeps pushing the rare disease paradigm as RNAi promises even wider indications

  With another rare disease approval under its belt, Alnylam is still revving up the R&D engines for new indications.

  Biotech

• 

  Prasad’s FDA appointment pressures cell and gene therapy stocks

  A vocal opponent of his predecessor Peter Marks, Dr. Vinay Prasad will now lead the office tasked with reviewing some genetic medicines, adding more uncertainty to an already struggling field of research.

  Biotech

• 

  With TV ads under threat, here’s how pharma can leverage social media

  RFK Jr.’s plan to ban TV advertising may shift more marketing attention to online platforms.

  Commercialization

• 

  On tariffs and pricing, Big Pharma CEOs are waiting out the storm while planning for the worst

  Chief executives at the largest drugmakers in the world are confident tariffs and pricing measures won’t be a major problem. But they’re still poised for change.

  Leadership

• 

  After an up and down year, pharma’s R&D landscape is shifting again

  While clinical trial funding was up, deal-making was down, and new uncertainties are coming into the picture.

  Biotech

• 

  With compounders out of the way, Lilly and Novo go after each other

  The two obesity leaders are pulling on all levers to stay on top of the market.

  Commercialization

• 

  Is pharma ready to let go of animal testing?

  Regulators have signaled their willingness to embrace alternative tests and guide the industry in new directions.  

  Biotech

• 

  Q&A

  Can real-world evidence bear some of the burden left by NIH cuts? This CEO sees an opportunity.

  Turmoil at the NIH has led to handwringing among researchers and drugmakers who rely on public funding. 

  Biotech

• 

  J&J scores FDA OK for immune drug touted as future blockbuster

  The company has predicted that Imaavy — now approved for myasthenia gravis — could eventually earn more than $5 billion in annual sales at its peak.

  Pharma

• 

  US backlash against mRNA vaccines could hinder scientific progress

  U.S. health agencies are taking the fight to vaccine and mRNA research, which could have lasting repercussions on medical and scientific advancements.

  Biotech

• 

  Is the FDA headed for a major reorganization?

  A leaked document revealed details about changes that could impact how the agency operates, but recent comments from FDA Commissioner Dr. Marty Makary have muddied the picture. 

  Pharma

• 

  Flagship’s latest venture reflects more than 25 years of leaping into the unknown

  A new AI-based company launched by the prolific venture capital firm Flagship Pioneering marks another platform approach in forward-thinking early science.

  Biotech

• 

  FDA’s job cuts paint mixed picture for drugmakers’ R&D plans

  After a 20% cut to the FDA’s workforce, biotechs and pharmas are bracing for delays. But the impacts won’t be consistent.

  Pharma